Connect with us

International Circuit

Alcami Expands Its Sterile Fill-Finish Capacity With Acquisition Of TriPharm Services

Alcami Corporation (“Alcami”), a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, today announced it has acquired TriPharm Services (“TriPharm”), a new state-of-the-art sterile fill-finish manufacturing center located near Research Triangle Park, North Carolina. The acquisition of TriPharm follows the recently announced $17 million expansion of Alcami’s sterile fill-finish facility in Charleston, South Carolina.

In conjunction with this acquisition, funds affiliated with Madison Dearborn Partners, LLC (“MDP”), Alcami’s existing majority owner, made an additional equity investment to fund Alcami’s growth plan and the former majority owner of TriPharm, Ampersand Capital Partners, rolled a portion of its TriPharm ownership interest into an ownership interest in Alcami.

TriPharm’s facility bolsters Alcami’s existing sterile fill-finish business, adding new prefilled syringe capabilities and isolator technology, while also providing incremental flexible sterile fill-finish and lyophilization capacity to meet growing industry demand. TriPharm’s new manufacturing facility is expected to be operational beginning in the second half of 2020.

“Our combination with TriPharm is an important next step in the execution of Alcami’s strategy to focus investments across our network to better serve rapidly growing specialized market segments,” said Alcami Interim Chief Executive Officer George Van Kula. “TriPharm expands our existing capabilities and provides additional equipment lines that will allow us to better serve the fast-developing biologics market segment.”

“As drug makers increasingly shift their focus toward more specialized, targeted therapeutics, and current injectable drug shortages hamper patient care, sterile fill-finish operations at proper scale are highly valued,” said TriPharm Co-Founder and Chief Executive Officer Patrick D. Walsh. “Our Research Triangle Park facility is designed to address this highly specialized industry demand.”

“TriPharm represents a compelling opportunity for Alcami to capitalize on building an industry-leading position in attractive and growing end-markets, as pharmaceutical and biopharmaceutical companies increasingly rely on contract development and manufacturing organizations to manage highly technical sterile fill-finish operations,” said Alcami Chairman Harry Kraemer. “I look forward to working closely with the Alcami and TriPharm teams to ensure sustained growth in sterile fill-finish for Alcami.-PR Newswire

Copyright © 2024 Medical Buyer

error: Content is protected !!